Major Response to Imatinib Mesylate in <i>KIT</i>-Mutated Melanoma
F. Stephen Hodi(Dana-Farber Cancer Institute), David E. Fisher(Dana-Farber Cancer Institute)
Cited by 414
Related Papers
Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced Cancer
|JAMA Oncology|2016|750
Imatinib for Melanomas Harboring Mutationally Activated or Amplified <i>KIT</i> Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
|Journal of Clinical Oncology|2013|592
c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi
|Genes & Development|2000|517
Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma
|Journal of Clinical Oncology|2017|480
Melanoma: from mutations to medicine
|Genes & Development|2012|476